title: Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
abstract: The first nonclinical drug development tool (DDT) advanced by the Critical Path to TB Drug Regimens (CPTR) Initiative through a regulatory review process has been endorsed by leading global regulatory authorities. DDTs with demonstrated predictive accuracy for clinical and microbiological outcomes are needed to support decision making. Regulatory endorsement of these DDTs is critical for drug developers, as it promotes confidence in their use in Investigational New Drug and New Drug Application filings. The in vitro hollow fiber system model of tuberculosis (HFS-TB) is able to recapitulate concentration-time profiles (exposure) observed in patients for single drugs and combinations, by evaluating exposure measures for the ability to kill tuberculosis in different physiologic conditions. Monte Carlo simulations make this quantitative output useful to inform susceptibility breakpoints, dosage, and optimal combination regimens in patients, and to design nonclinical experiments in animal models. The Pre-Clinical and Clinical Sciences Working Group within CPTR executed an evidence-based evaluation of the HFS-TB for predictive accuracy. This extensive effort was enabled through the collaboration of subject matter experts representing the pharmaceutical industry, academia, product development partnerships, and regulatory authorities including the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A comprehensive analysis plan following the regulatory guidance documents for DDT qualification was developed, followed by individual discussions with the FDA and the EMA. The results from the quantitative analyses were submitted to both agencies, pursuing regulatory DDT endorsement. The EMA Qualification Opinion for the HFS-TB DDT was published 26 January 2015 (available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000319.jsp).
authors.affiliation: Critical Path Institute, Tucson, Arizona.
authors.forename: Klaus
authors.initials: K
authors.lastname: Romero
authors.affiliation: Critical Path Institute, Tucson, Arizona.
authors.forename: Robert
authors.initials: R
authors.lastname: Clay
authors.affiliation: Critical Path Institute, Tucson, Arizona.
authors.forename: Debra
authors.initials: D
authors.lastname: Hanna
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D017277:Drug Approval; D055808:Drug Discovery / Q000331:legislation & jurisprudence / Q000379:methods; D004345:Drug Industry; D015507:Drugs, Investigational / Q000592:standards / Q000627:therapeutic use; D006801:Humans; D008954:Models, Biological; D009010:Monte Carlo Method; D011237:Predictive Value of Tests; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000995:Antitubercular Agents; D015507:Drugs, Investigational
keywords: drug development tools; model-based drug design; quantitative pharmacology; regulatory science; tuberculosis